Lost in translocation: The functions of the 18-kD translocator protein

Trends in Endocrinology and Metabolism

Volumn 26, Issue 7, 2015, Pages 349-356

  Gut, Philipp ^a   Zweckstetter, Markus ^b,c,d   Banati, Richard B ^e,f  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cholesterol; Heme metabolism; Mitochondrial permeability transition pore; Neuroimaging; Neuroinflammation; Peripheral benzodiazepine receptor; REV ERB

Indexed keywords

CARRIER PROTEIN; NEUROSTEROID; 4 AMINOBUTYRIC ACID RECEPTOR; BZRP PROTEIN, MOUSE; CHOLESTEROL; TSPO PROTEIN, HUMAN;

CELL STRESS; CHOLESTEROL TRANSPORT; HORMONAL REGULATION; KNOCKOUT MOUSE; LOSS OF FUNCTION MUTATION; METABOLIC STRESS; MITOCHONDRION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; STEROIDOGENESIS; ANIMAL; GENETICS; HUMAN; METABOLISM;

ANIMALS; CHOLESTEROL; HUMANS; MITOCHONDRIA; RECEPTORS, GABA;

EID: 84937520495     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.04.001     Document Type: Review

References (84)

1. Anholt R.R., et al. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem. 1986, 261:576-583.
2. Antkiewicz-Michaluk L., et al. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. Mol. Pharmacol. 1988, 34:272-278.
3. Benavides J., et al. In vivo labelling in several rat tissues of 'peripheral type' benzodiazepine binding sites. Eur. J. Pharmacol. 1984, 99:1-7.
4. Papadopoulos V., et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997, 62:21-28.
5. Anholt R.R., et al. Depletion of peripheral-type benzodiazepine receptors after hypophysectomy in rat adrenal gland and testis. Eur. J. Pharmacol. 1985, 110:41-46.
6. Papadopoulos V., et al. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:5113-5117.
7. Papadopoulos V., et al. Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology 1991, 129:1481-1488.
8. Li H., Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998, 139:4991-4997.
9. Gavish M., et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999, 51:629-650.
10. Papadopoulos V., et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
11. Liu G.J., et al. The 18kDa translocator protein, microglia and neuroinflammation. Brain Pathol. 2014, 24:631-653.
12. Yeliseev A.A., et al. A mammalian mitochondrial drug receptor functions as a bacterial "oxygen" sensor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5101-5106.
13. Rupprecht R., et al. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2010, 9:971-988.
14. Thompson M.M., et al. Translocator protein 18kDa (TSPO) is regulated in white and brown adipose tissue by obesity. PLoS ONE 2013, 8:e79980.
15. 3H]PK11195 binding to activated microglia. J. Neurocytol. 1997, 26:77-82.
16. Le Fur G., et al. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 1983, 32:1839-1847.
17. Banati R.B., et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat. Commun. 2014, 5:5452.
18. Daugherty D.J., et al. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol. Med. 2013, 5:891-903.
19. Barron A.M., et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:8891-8897.
20. Kondo D., et al. Peripheral-type benzodiazepine receptor antagonist is effective in relieving neuropathic pain in mice. J. Pharmacol. Sci. 2009, 110:55-63.
21. Decaudin D., et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002, 62:1388-1393.
22. Bribes E., et al. Involvement of the peripheral benzodiazepine receptor in the development of rheumatoid arthritis in Mrl/lpr mice. Eur. J. Pharmacol. 2002, 452:111-122.
23. Gut P., et al. Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat. Chem. Biol. 2013, 9:97-104.
24. Obame F.N., et al. Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J. Pharmacol. Exp. Ther. 2007, 323:336-345.
25. Rupprecht R., et al. Translocator protein (18kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
26. Veenman L., Gavish M. The role of 18kDa mitochondrial translocator protein (TSPO) in programmed cell death, and effects of steroids on TSPO expression. Curr. Mol. Med. 2012, 12:398-412.
27. Sileikyte J., et al. Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (translocator protein of 18kDa (TSPO)). J. Biol. Chem. 2014, 289:13769-13781.
28. Tu L.N., et al. Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. J. Biol. Chem. 2014, 289:27444-27454.
29. Morohaku K., et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 2014, 155:89-97.
30. Tu L.N., et al. PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). Endocrinology 2014, 156:1033-1039.
31. Sprengel R., et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J. Biol. Chem. 1989, 264:20415-20421.
32. Joseph-Liauzun E., et al. Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure. J. Biol. Chem. 1998, 273:2146-2152.
33. Murail S., et al. Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. Biochim. Biophys. Acta 2008, 1778:1375-1381.
34. Galvagnion C., et al. Production and initial structural characterization of the TM4TM5 helix-loop-helix domain of the translocator protein. J. Pept. Sci. 2013, 19:102-109.
35. Korkhov V.M., et al. Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals. Structure 2010, 18:677-687.
36. Li F., et al. Characterization and modeling of the oligomeric state and ligand binding behavior of purified translocator protein 18kDa from Rhodobacter sphaeroides. Biochemistry 2013, 52:5884-5899.
37. Jaremko L., et al. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 2014, 343:1363-1366.
38. Li F., et al. Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science 2015, 347:555-558.
39. Owen D.R., et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J. Nucl. Med. 2011, 52:24-32.
40. Guo Y., et al. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science 2015, 347:551-555.
41. Lacapere J.J., et al. Structural and functional study of reconstituted peripheral benzodiazepine receptor. Biochem. Biophys. Res. Commun. 2001, 284:536-541.
42. Li H., et al. Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1267-1272.
43. Jamin N., et al. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol. Endocrinol. 2005, 19:588-594.
44. Jaremko L., et al. Toward the functional oligomerization state of tryptophan-rich sensory proteins. Protein Sci. 2014, 23:1154-1160.
45. Hinsen K., et al. Construction and validation of an atomic model for bacterial TSPO from electron microscopy density, evolutionary constraints, and biochemical and biophysical data. Biochim. Biophys. Acta 2015, 1848:568-580.
46. Delavoie F., et al. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 2003, 42:4506-4519.
47. Selvaraj V., Stocco D.M. The changing landscape in translocator protein (TSPO) function. Trends Endocrinol. Metab. 2015, 26:341-348.
48. Sileikyte J., et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J. Biol. Chem. 2011, 286:1046-1053.
49. Mukhin A.G., et al. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:9813-9816.
50. Ritta M.N., Calandra R.S. Testicular interstitial cells as targets for peripheral benzodiazepines. Neuroendocrinology 1989, 49:262-266.
51. Papadopoulos V. On the role of the translocator protein (18-kDa) TSPO in steroid hormone biosynthesis. Endocrinology 2014, 155:15-20.
52. Hirschey M.D., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
53. Wagner G.R., Hirschey M.D. Nonenzymatic protein acylation as a carbon stress regulated by sirtuin deacylases. Mol. Cell 2014, 54:5-16.
54. He W., et al. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol. Metab. 2012, 23:467-476.
55. Scarffe L.A., et al. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014, 37:315-324.
56. Gautier C.A., et al. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11364-11369.
57. Tufi R., et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat. Cell Biol. 2014, 16:157-166.
58. Dawson T.M., et al. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
59. Grenier K., et al. Parkin- and PINK1-dependent mitophagy in neurons: will the real pathway please stand up?. Front. Neurol. 2013, 4:100.
60. Gatliff J., et al. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. Autophagy 2014, 10:2279-2296.
61. Vafai S.B., Mootha V.K. Mitochondrial disorders as windows into an ancient organelle. Nature 2012, 491:374-383.
62. Hirsch J.D., et al. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol. Pharmacol. 1989, 35:157-163.
63. 0-ATPase by ligands of the peripheral benzodiazepine receptor. Bioorg. Med. Chem. Lett. 2007, 17:1667-1670.
64. 0-ATP synthase in Bcl-2 knock-down cells. Curr. Mol. Med. 2012, 12:476-482.
65. Lin R., et al. Genetic analysis of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Ab42-induced neurodegeneration. Aging Cell 2014, 13:507-518.
66. Vander Heiden M.G., et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:325-334.
67. Tschop M.H., et al. A guide to analysis of mouse energy metabolism. Nat. Methods 2012, 9:57-63.
68. Rampon C., et al. Translocator protein (18kDa) is involved in primitive erythropoiesis in zebrafish. FASEB J. 2009, 23:4181-4192.
69. Ginter C., et al. Chemical catalysis by the translocator protein (18kDa). Biochemistry 2013, 52:3609-3611.
70. Domazet-Loso T., Tautz D. An ancient evolutionary origin of genes associated with human genetic diseases. Mol. Biol. Evol. 2008, 25:2699-2707.
71. Dickerson J.E., et al. Defining the role of essential genes in human disease. PLoS ONE 2011, 6:e27368.
72. Lopez-Bigas N., et al. Highly consistent patterns for inherited human diseases at the molecular level. Bioinformatics 2006, 22:269-277.
73. Capra J.A., et al. How old is my gene?. Trends Genet. 2013, 29:659-668.
74. Owen D.R., et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab. 2012, 32:1-5.
75. Colasanti A., et al. Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18kDa translocator protein (TSPO). Psychoneuroendocrinology 2013, 38:2826-2829.
76. Svahn A.J., et al. Emergent properties of microglia. Brain Pathol. 2014, 24:665-670.
77. Graeber M.B. Neuroinflammation: no rose by any other name. Brain Pathol. 2014, 24:620-622.
78. Bernassau J.M., et al. A 3D model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. J. Mol. Graph. 1993, 11:236-244. 235.
79. Gut P., Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature 2013, 502:489-498.
80. Wu N., et al. Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbα. Genes Dev. 2009, 23:2201-2209.
81. Yin L., et al. Rev-erbα, a heme sensor that coordinates metabolic and circadian pathways. Science 2007, 318:1786-1789.
82. Handschin C., et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1α. Cell 2005, 122:505-515.
83. Estall J.L., et al. PGC-1α negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erbα axis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22510-22515.
84. Fennell D.A., et al. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. Br. J. Cancer 2001, 84:1397-1404.